Synova Capital Invests in Charnwood Molecular
January 1, 2020
Synova Capital has completed a significant growth investment into Charnwood Molecular to support the company's next phase of expansion. The funding will be used to accelerate Charnwood’s development of higher‑value chemistry, broaden its scientific service offering, and pursue selective acquisitions to expand capabilities and address strong demand from pharma and biotech clients.
- Buyers
- Synova Capital
- Targets
- Charnwood Molecular
- Industry
- Biotechnology
- Location
- Leicestershire, United Kingdom
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Synova Invests Growth Capital into 3173 Limited
June 1, 2022
Financial Services
Growth investor Synova has made a growth capital investment into 3173 Limited, a Belfast-based provider of pensions administration software (Mantle), trusteeship and actuarial services. The funding will support scaling of the Mantle SaaS platform, expansion of core services into new geographies and service lines, and selective strategic acquisitions; the deal is subject to FCA approval.
-
Synova Makes Growth Investment in National Education Group
October 1, 2021
Education
Growth investor Synova has made a significant minority (growth-capital) investment in National Education Group (NEG), a UK-based provider of online CPD training delivered via a proprietary learning management system. The capital will support further investment in NEG’s software platform and digital content library to accelerate product development, content creation and international growth.
-
Limerston Capital‑backed Concept Life Sciences Acquires Charnwood Discovery
November 8, 2024
Healthcare Services
Limerston Capital‑backed Concept Life Sciences (CLS) has acquired Charnwood Discovery, a UK-based drug discovery contract research provider headquartered in Loughborough. The add-on strengthens CLS's integrated drug discovery, chemistry, biology and ADME/DMPK capabilities and expands its ability to accelerate drug candidates to clinic while providing customers access to CLS's broader translational biology and GMP manufacturing services.
-
Synova Invests in Mallcomm
November 1, 2022
Cloud & SaaS
Growth investor Synova has made an investment in Mallcomm to support a management buyout led by CEO David Fuller‑Watts. The capital will accelerate product development, support strategic M&A and geographic expansion of Mallcomm's PropTech SaaS platform, and brings Chris Blaxall onto the board as Executive Chairman.
-
SFW Capital Partners Makes Strategic Investment in Sannova Analytical
August 10, 2022
Biotechnology
SFW Capital Partners completed a strategic growth investment in Sannova Analytical, a Somerset, New Jersey-based bioanalytical CRO that provides bioanalytical and CMC testing services to pharmaceutical and biotech companies. Founders and existing owners (including the Marepalli family, Dr. Venkat Reddy, Malleswar Kollu, and Geeta Vidiyala) are reinvesting and retaining an equity stake; SFW will support expansion of services, capacity, and pursue strategic acquisitions to accelerate growth.
-
Synova Invests Growth Capital in Unity Five Limited
September 1, 2022
Cloud & SaaS
Synova has made a growth capital investment in Unity Five Limited (Unity5), a UK-based provider of SaaS parking, traffic enforcement and permitting software. The funding will support Unity5’s product and capability expansion through targeted M&A and accelerate its international expansion across Europe and APAC, with co-founders Dave Herbert and Lukasz Kieruczenko retaining a material stake.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.